Skip to content
Sign in

Company

Formycon AG

Open structure map

Structure of Formycon AG

Formycon AG

Company

4 connections
PeersCompetition and partners
DownstreamCustomers
ConstraintsRegulation and exposure
Relationship began2026
Formycon AGCompany · 4 connections
Layer 1

DownstreamCustomers1

PeersCompetition and partners2

ConstraintsRegulation and exposure1

Place in the network

No. 6584 of 73094top 10%down 2203 places this week

3 direct links

In a group of 1157 closely linked entities, around

U.S. Food and Drug AdministrationFDAUS Food and Drug AdministrationLillyMerck

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

Showing 1 to 5 of 5

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
partners withZydus Lifesciences Limited

No public evidence summary is available.

BioPharma Dive · 2026-11-02 22:34

View evidence
FactEvidence 1
located inMartinsried

Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany.

PR Newswire news releases · 2026-10-13 21:30

View evidence
  • CompanyPR Newswire news releases2026-10-13 21:30
    Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany.
    View source
FactEvidence 1
employees200 employees

Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis through manufacturing and clinical testing to the documents for approval.

PR Newswire news releases · 2026-10-13 21:30

View evidence
  • CompanyPR Newswire news releases2026-10-13 21:30
    Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis through manufacturing and clinical testing to the documents for approval.
    View source
FactEvidence 1
approved biosimilars3 biosimilars

Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.

PR Newswire news releases · 2026-10-13 21:30

View evidence
  • CompanyPR Newswire news releases2026-10-13 21:30
    Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
    View source
FactEvidence 1
partners withCommercialization partners

Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.

PR Newswire news releases · 2026-10-13 21:30

View evidence
  • CompanyPR Newswire news releases2026-10-13 21:30
    Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
    View source
FactEvidence 1
suppliesFYB206

Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.

PR Newswire news releases · 2026-10-13 21:30

View evidence
  • CompanyPR Newswire news releases2026-10-13 21:30
    Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.
    View source

Showing 1 to 6 of 8

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance